Videos

Donna and Dr Gasparetto close the discussion by highlighting the importance of physicians utilizing their patients, as well as patients being involved with their multiple myeloma treatment.

Donna gives advice to other multiple myeloma patients about what she has learned from living with this disease and her various therapies.

Lori J. Wirth, MD, of Massachusetts General Hospital, comments on the role of molecular testing to guide treatment decisions in thyroid cancer and explains how personalized medicine differs from standard treatment approaches.

Benjamin Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, describes how molecular testing in non–small cell lung cancer has advanced and impacted treatment.

Ask the Experts is a question and answer session with two of the leading bladder cancer experts in the United States, Kent Mouw, MD, PhD and Sarah P Psutka, MD, MSc.

The Tigerlily Foundation and GRASP presents a conversation with Dr. Tisha M. Felder on what it means to have “Cancer While Black: How Trauma, Fear, Generational Pain & Mistrust Impact Breast Cancer.”

View the full CURE® Educated Patient® Webinar: Empowering Patients to Understand Cancer Genetic Testing and Counseling on demand.

Cristina Gasparetto, MD, discusses Donna’s next line of therapy, selinexor, and how being part of a clinical trial impacted her multiple myeloma.

Donna’s multiple myeloma treatment changes with the help of Dr Cristina Gasparetto’s direct influence and CAR T cell therapy.

Cristina Gasparetto, MD, discusses Donna’s relationship with the drug carfilzomib for multiple myeloma therapy, as well as her second relapse.

Donna and Dr Gasparetto converse about the many first- and second-line therapies for multiple myeloma.

Cristina Gasparetto, MD, details typical multiple myeloma maintenance in comparison with Donna’s therapies, and Donna tells us about her first relapse with multiple myeloma.

We learn more about Donna’s 2 transplants, her chemotherapy, and how they impacted her quality of life.

Donna discusses her multiple myeloma diagnosis and the start of her treatment, while Dr Gasparetto educates on the importance of transplants.

Cristina Gasparetto, MD, gives a brief overview of the multiple myeloma disease state and introduces us to Donna, one of her patients diagnosed with multiple myeloma.

Patients with cancer can advocate for themselves by researching their illnesses and treatments before an appointment, so they’re able to ask better questions, says an expert from the HealthTree Foundation for Multiple Myeloma.

An expert thoracic oncologist, Adam J. Schoenfeld, MD, highlights key factors that patients and providers should take into account when considering cell therapy in non–small cell lung cancer.

A key opinion leader in the management of lung cancer offers insight into ongoing clinical trials of tumor-infiltrating lymphocyte (TIL) therapy in non–small cell lung cancer.

New advances in research around immunotherapies for patients with myeloma are on the horizon, according to an expert from the HealthTree Foundation & Myeloma Crowd.

Adam J. Schoenfeld, MD, considers the benefits and limitations of tumor-infiltrating lymphocyte (TIL) therapy and discusses its potential impact on the treatment landscape in non–small cell lung cancer.

An expert in the management of non–small cell lung cancer defines tumor-infiltrating lymphocyte (TIL) therapy by discussing its mechanism of action and reviewing its impact in other disease states, such as myeloma.

A key opinion leader in thoracic oncology discusses factors to consider regarding emerging cell therapy options in non–small cell lung cancer, such as CAR T, TCR, and TIL therapies.

Adam J. Schoenfeld, MD, provides key insights into treatment options for patients with non–small cell lung cancer whose tumors progress after first-line therapy.

Bonnie Addario, a lung cancer survivor, explains the importance of comprehensive biomarker testing in patients with lung cancer to treat to target and coverage from insurance companies.

G. Paris Johnson is a long-term survivor of pancreatic cancer. She is now focused on advocacy and making the most of her life.